Indivior has paid 15.95 million pounds sterling ($20.4 million) to C4X Discovery for the full rights to the British biotech’s orexin-1 receptor antagonist being developed for substance use disorder.
C4XD and Garvan Institute of Medical Research report successful patient stratification approach using C4XD's new precision medicine platform PatientSeek
C4X Discovery (C4XD) and AstraZeneca have entered an exclusive global licensing agreement worth up to $402m to develop oral therapy to treat inflammatory and respiratory ailments.
MANCHESTER, UK / ACCESSWIRE / July 6, 2022 / C4X Discovery Holdings plc (AIM:C4XD), a pioneering Drug Discovery company, today announces that it has received a milestone payment of €3 million from Sanofi under the IL-17A Inhibitor programme license agreement entered into in April 2021.